Torrent Pharma Eyes Rs 450 Crore Savings Through JB Pharma Integration
New Delhi: Torrent Pharmaceuticals is aiming to generate annual synergies of around Rs 450 crore from its acquisition of JB Chemicals & Pharmaceuticals (JB Pharma) by integrating operations, reducing costs, rationalising overlapping products and expanding cross-selling opportunities, as the company works to maximise returns from one of the largest acquisitions in India's pharmaceutical sector.
Torrent acquired a 48.8% controlling stake in KKR-controlled JB Pharma in January 2026 and is now moving ahead with the acquisition of the remaining 51.2% stake through a share-swap merger. Under the approved merger scheme, Torrent will issue 51 equity shares for every 100 shares held by JB Pharma shareholders. The scheme has already secured shareholder approval and is currently awaiting the final sanction of the National Company Law Tribunal (NCLT).
In his message to shareholders in the company's latest annual report, Torrent Pharma Managing Director Aman Mehta described the acquisition as a transformational milestone that significantly strengthens the company's domestic and international business. He said the transaction enhances Torrent's scale in the Indian pharmaceutical market, broadens its therapeutic portfolio, deepens its presence in chronic therapies and strengthens its global footprint.
The company expects the projected Rs 450 crore annual synergies to come from multiple integration initiatives, including manufacturing optimisation, procurement efficiencies, supply chain improvements, elimination of duplicate functions, portfolio rationalisation and cost reductions. Torrent also plans to review overlapping brands and product offerings while discontinuing selected products where necessary to improve operational efficiency and profitability.
A key component of the integration strategy will be cross-selling across the combined sales network. Torrent intends to leverage the complementary product portfolios and the expanded field force of both companies to improve market penetration, strengthen relationships with healthcare professionals and accelerate revenue growth across key therapeutic segments.
The acquisition is also expected to reinforce Torrent's leadership in India's branded pharmaceutical market by expanding its presence in chronic care therapies while providing access to JB Pharma's established brands. At the same time, the integration is expected to strengthen Torrent's international operations by combining JB Pharma's overseas business with its existing global network, thereby improving market access, distribution capabilities and overall operational scale.
Management indicated that the integration strategy extends beyond cost savings and will also focus on revenue enhancement through portfolio optimisation, manufacturing efficiencies and wider commercial reach. The company believes these initiatives will improve profitability while creating long-term value from the acquisition.
According to a recent media report published by Moneycontrol, Torrent Pharma views the JB Pharma acquisition as a strategic move that will deliver nearly Rs 450 crore in annual synergies through cost optimisation, portfolio pruning, manufacturing efficiencies, procurement savings and cross-selling opportunities. The report states that the transaction is expected to strengthen Torrent's domestic leadership, expand its chronic care portfolio, enhance its international presence and position the combined entity for sustained long-term growth.
